BioVie Inc (NAS:BIVI)
$ 2.8 0.09 (3.32%) Market Cap: 49.75 Mil Enterprise Value: 33.44 Mil PE Ratio: 0 PB Ratio: 1.58 GF Score: 31/100

BioVie Inc at LifeSci Advisors Virtual Corporate Access Event Transcript

Jan 07, 2022 / 03:00PM GMT
Release Date Price: $48.8 (-6.87%)
Jason Laffin
LIfeSci Consulting - Moderator

Good morning, everyone, and thank you for attending LifeSize 11th Annual Corporate Access Event. My name is Jason Laffin, and I'm a managing partner at LifeSci Consulting. I have the pleasure today of moderating this panel called The Best of Both Worlds: Defining Yourself When You Fit Into More Than One Basket. Today, we are going to be discussing how successful biotech companies navigate advancing two unrelated pipeline assets, and the key considerations encountered by management teams. These include decisions around resource and capital allocation, as well as asset prioritization, dialogue with the Board, and concisely communicating the story and strategic rationale to investors.

Joining me on this panel are Magnus Corefitzen, CEO of Ascelia Pharma, Cuong Do, CEO of BioVie, Carlos Buesa, CEO of Oryzon, and Marco Taglietti, CEO of SCYNEXIS. Today's session will last approximately 45 minutes, which will include a brief Q&A session at the end, time permitting. The audience can submit questions at the bottom of the window via the Q&A tab.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot